Glycans Meet Sphingolipids: Rational Structure-Based Design of a New Generation of Sphingosine Kinase Inhibitors

PS1 Poster session 1 Odd numbers
Location (hall): 
Start/end time: 
Monday, July 1, 2019 - 15:45 to 17:15

Federica Compostella2, Athanasios Athanasios Papakyriakou3, Laura Morelli2, Elisa Puliti4, Francesca Cencetti4, Paola Bruni4, Barbara Richichi1

1University of Florence, Department of Chemistry 'Ugo Schiff', Sesto Fiorentino, Italy, 2University of Milan, Department of Medical Biotechnology and Translational Medicine, Milano, Italy, 3Institute of Biosciences & Applications, NCSR “Demokritos”, Athenes, Greece, 4Department of Experimental and Clinical Biomedical Sciences, University of Florence, Firenze, Italy

Sphingosine kinases, SK1 and SK2, are enzymes localized respectively in the cytosol and in intracellular compartments, which catalyze the production of sphingosine-1-phosphate (S1P) in an ATP-dependent manner. Solid experimental evidences implicate the S1P axis in different pathological conditions (e.g. cancer, inflammatory disease, fibrosis), and aberrant S1P levels and/or SKs expression have been associated with diseases progression [1]. In this regards, the manipulation of S1P axis using chemical tools has been exploited either looking at the inhibition of SK activity and by the modulation of S1P receptors signaling. Specifically, a wide number of SK1 inhibitors have been developed to date. However, most of them are still limited by low potency and/or specificity among SK subtypes, indicating the need for new and more efficient SK1 inhibitors.

In this framework, we report here on an original approach for the rational structure-based design of SK1 inhibitors. It relies on the integration of the information coming from the SK1-co-crystal structure of known validated inhibitors into pharmacophoric models. This approach aims at the development of better ‘molecular fitting’ inhibitors by using glycans as an anchoring polar head allowing to hold inhibitors at the J-shaped hydrophobic binding pocket of SK [2]. In particular, in this communication we report on the rational structure-based design and stereoselective synthesis of glycan-containing PF543 analogues (Figure 1), one of the most potent SK1 inhibitors reported so far. Moreover, a preliminary evaluation of the role of the new synthesized SK inhibitors in TGFβ-induced fibrosis of murine myoblasts to confirm the rationale of the proposed approach is described.

Figure 1

  1. Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. Prog Lipid Res. 2016, 62:93-106
  2. Wang J, Knapp S, Pyne NJ, Pyne S, Elkins JM Crystal Structure of Sphingosine Kinase 1 with PF-543. ACS Med. Chem. Letters 2014, 5, 1329-1333